The Effect of the Alpha-7 Nicotinic AChR Agonist GTS-21 on Inflammation and End-Organ Dysfunction During Human Endotoxemia.

Trial Profile

The Effect of the Alpha-7 Nicotinic AChR Agonist GTS-21 on Inflammation and End-Organ Dysfunction During Human Endotoxemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs GTS 21 (Primary) ; Escherichia coli lipopolysaccharide; Lipopolysaccharide
  • Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Nov 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 04 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top